Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use

By afschroeder • August 2, 2026

Peng DS, Shen A, Smart C, Galamgam J. Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use. JAAD Case Rep. 2026 Jun 12;74:247-250. doi: 10.1016/j.jdcr.2026.06.006. PMID: 42541308; PMCID: PMC13427499.

Tags: cutaneous adverse drug reaction, Dermatology, drug hypersensitivity, dual GLP-1/GIP agonists, eosinophilic spongiotic dermatitis, exanthematous drug eruption, GLP-1 receptor agonists, morbilliform drug eruption, pharmacovigilance, Publications, Resident, Systemic therapy, tirzepatide, type IV hypersensitivity

Hantavirus for the dermatologist

Shen CZ, Adams J, Freeman EE, Goh C, Rosenbach M; American Academy of Dermatology’s Emerging Diseases Task Force. Hantavirus for the dermatologist. J Am Acad[...]

A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel

Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, Armstrong A, Boh E, Gottlieb AB, Khattri S, Litchman G, Merola J, Murina[...]

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains

Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, Armstrong AW, Gottlieb AB, Han G, Khattri S, Shaigany S, Weinberg JM, Lebwohl[...]